Pfizer CEO: How AI Will Reshape the Future of Medicine | Podcast

ELI5/TLDR

Pfizer’s CEO Albert Bourla sat down with the head of Norway’s giant sovereign wealth fund. He says the COVID windfall ($56bn in 2022 revenue, now $6bn) got poured into roughly $80bn of acquisitions, mostly betting on a new kind of cancer drug. The two things keeping him up at night are AI and China — AI because it could halve the cost and triple the speed of inventing medicines, and China because its drug industry is already doing exactly that and may overtake the West within two years. His advice to America: stop trying to slow China down, and instead try to get better.

The Full Story

The money question after COVID

When the pandemic ended, Pfizer had a problem most companies would envy: a mountain of cash and a decision to make. Bourla frames the cash as the smaller asset. The bigger one was belief — the proof that “when we put our will together, we can bend every curve.”

Now it is six. So it was a huge drop.

That is COVID revenue: $56 billion in 2022, $6 billion now. The stock went from best performer to worst. Bourla admits he privately wondered if he was a failure “just months after I was the hero of the world.” His whole organization had been quietly using the share price as a scoreboard, and the scoreboard had collapsed.

He had three options for the cash — pay a dividend, buy back shares (then trading around $50), or invest in the business. He chose to invest, spending more than $80 billion on acquisitions. Three deals make up 80% of that spend, and, in his words, “the jury’s out.”

The cancer bet: precision missiles

The biggest deal was Seagen, bought for more than $40 billion. The whole thing was a bet on one technology: ADCs, or antibody drug conjugates. Here is the idea, in his own analogy.

Think of chemotherapy as carpet-bombing — it poisons cancer cells but also healthy ones, which is why it makes people so sick. An ADC is a guided missile instead. It has two parts. One part, the antibody, is the GPS: it is built to recognize one specific address in the body — a kind of cell in the liver, the brain, the bone — and stick to it. The other part is the warhead, the actual drug. The missile flies to the cancer, and only then releases its payload.

Imagine chemotherapy that doesn’t go everywhere but goes predominantly to the cancer cells.

The reason Pfizer paid up is that you can mix and match. Swap the GPS to target a different organ; swap the warhead for radioactive material, or chemo, or something else. That combinatorial flexibility is the prize. Seagen was the only player with four such drugs already on the market and 13 more in trials.

The obesity scramble

The other big move was buying a company Bourla calls MyThera (outbidding Novo Nordisk) to get into weight-loss drugs — the GLP-1 boom led by Ozempic and Mounjaro. Pfizer had its own obesity pills in development and lost them: two promising candidates showed signs of liver toxicity and had to be killed. Bad scientific luck. Pfizer had the salesforce, the factories, the trial machinery — but suddenly no product to sell. The acquisition filled that hole.

The good news since buying it: data confirmed they have a monthly injection, while rivals Lilly and Novo are weekly. Whether it works better or worse than Lilly’s is still up for debate, but monthly versus weekly is a real differentiator.

Fixing a “mediocre” returns engine

Bourla makes an unusually blunt admission. By most lab metrics, Pfizer’s research is top-tier — its clinical success rate is 18-19% versus an industry norm around 10-11%, and its regulatory approval rate is near 95%. Yet for years the company was, in his word, “mediocre” at the one metric that matters: dollars out versus dollars in.

The diagnosis: not a capability problem, a focus problem. Scientists chased anything with positive data, silos divided research from the commercial side, and the company kept building technically impressive drugs that few people would actually buy.

If it is a question of focus with good capabilities but wrong focus, that’s a cultural, that’s a governance, that’s a leadership issue you can change within months.

So he swapped in new R&D leaders — not better scientists, but scientists “that can focus” — and merged the early and late research teams under one roof to fix the riskiest moment in drug development: the handoff when one team’s discovery becomes another team’s job to prove.

AI: the problem isn’t the tech anymore

On AI curing all disease in 10-15 years, Bourla calls it an exaggeration that makes a fair point. He won’t say all disease will be cured, but he expects a “very different level of standards of care” within five years, driven by AI plus advances in biology together.

His sharpest observation: the bottleneck is no longer the technology. The models can already do far more than companies use them for. The gap — he calls it a “technology overhang” — is organizational. People don’t adopt AI because of inertia and fear: fear for their jobs, and fear of a thing they don’t understand. The fix is AI literacy. Pfizer is running thousands of staff through training and building a certification system. Bourla took the weekend course himself and saw a “huge difference.” Tangen pushes him on whether it should be mandatory; Bourla concedes it probably should, because the people who need it most are the least eager.

He also picked a side on how to organize AI: not a central team of visionaries dictating to everyone, but decentralized — the center provides the plumbing (data, cloud, compute), and each unit owns the accountability for finding real uses.

China: the genie is out of the bottle

This is the part with teeth. Bourla describes China’s pharma rise as a deliberately executed five-year plan. The evidence he cites: in a ranking of universities by scientific output, the top 10 used to be eight American (MIT, Harvard). In 2025, only one (Harvard) was American — eight were Chinese.

How? Not just research spending. He credits two unglamorous fixes: a credible, non-corrupt regulator (modeled on visits to the US FDA), and strong intellectual property protection with a fast court system — because a biotech’s entire asset is “a formula on a piece of paper,” and nobody invests if that paper isn’t protected.

They are doing everything with half the cost and three times the speed.

He thinks China is not yet ahead in oncology but will be within one or two years in early-stage work — chemistry, preclinical, molecule development — where for every one program Pfizer runs, China has ten companies running. For now they license molecules to Pfizer (he did a deal with a Chinese biotech called 3SBio), but he is clear that is temporary: China will eventually take its drugs to market alone, the way it did with EVs, solar panels and batteries.

His prescription for the US is contrarian: stop spending 80% of the effort trying to slow China down (“you will never slow them down, the genie is out of the bottle”) and spend it getting better instead — via regulatory reform, NIH funding, university reform, and fixing drug-pricing policy, which he blames for driving biotech funding to a historic low in 2025.

Culture eats strategy

On leadership, Bourla ranks the four levers of a company: structure matters least, then strategy, then leadership, and most of all, culture. His reasoning is practical — you cannot staff thousands of people entirely with A-players, but the right culture lifts everyone a grade: C’s become C-plus, A’s become triple-A. He has himself rated by subordinates and peers every six months (he flipped the usual top-down review on its head when he became CEO). His main self-improvement target: being a passionate Mediterranean who, from the top seat, can accidentally shut people up — so he runs deliberate “rounds” to make everyone speak.

The drive, he says, traces to his mother, a Holocaust survivor who was pulled from a firing squad at the last moment. She never spoke of hate, only of the celebration of life. Her line, when young Albert complained homework was too hard: “Don’t tell me you can’t do it. I survived the firing squad. Go and do it.”

Key Takeaways

Pfizer’s COVID revenue fell from $56bn (2022) to $6bn, and the windfall funded roughly $80bn in acquisitions; three deals account for 80% of that spend.
The $40bn+ Seagen deal was a bet on ADCs — antibody drug conjugates — which work like guided missiles: an antibody acts as GPS to a specific cell type, delivering a drug “warhead” only at the target, sparing healthy tissue.
ADCs are valuable because they’re modular: swap the targeting antibody to hit different organs, swap the payload (chemo, radioactive, etc.) for different effects.
Pfizer entered obesity by acquisition (outbidding Novo Nordisk) after its own oral candidates failed on liver toxicity; the bought asset offers a monthly injection vs rivals’ weekly.
Pfizer’s clinical success rate is 18-19% vs an industry ~10-11%, and regulatory approval ~95% — but for years it converted those wins into mediocre financial returns due to poor commercial focus and R&D/commercial silos.
Bourla’s view: the AI bottleneck is organizational, not technical — a “technology overhang” where models can do more than companies use them for, blocked by employee inertia and fear.
Pfizer favors decentralized AI: central team provides data/compute infrastructure, individual units own accountability for use cases.
China’s pharma rise is a five-year-plan execution: it built a credible FDA-style regulator and strong IP protection with fast patent courts to attract biotech investment.
In 2025, only one of the world’s top 10 universities by scientific output (Harvard) was American; eight were Chinese.
China operates at “half the cost and three times the speed”; Bourla expects it to lead early-stage drug discovery within 1-2 years, comparing the trajectory to EVs, solar and batteries.
Bourla’s leadership hierarchy: culture > leadership > strategy > structure. “Culture eats strategy for lunch.”
Paxlovid (the COVID antiviral pill) was, per Bourla, the first machine-learning-discovered molecule with major impact — AI helped more with the treatment than the vaccine.

Claude’s Take

This is a high-quality interview because the interviewer is a peer, not a journalist — Tangen runs the world’s largest sovereign wealth fund and is a Pfizer shareholder, so Bourla talks like he’s in a board meeting, not a press conference. That produces unusually candid lines: admitting Pfizer was “mediocre” at returns, admitting he privately feared he was a failure, and conceding the jury is still out on his $80bn shopping spree.

The China segment is the most valuable and the most genuinely alarming, and it’s the part where Bourla has the least incentive to spin — he’s making the case for policy help, so he benefits from sounding the alarm. The “eight of ten top universities are Chinese” stat is striking but worth a grain of salt; “scientific output” rankings (this sounds like the Nature Index) measure publication volume in selected journals, which favors scale and isn’t the same as the best science. The “half the cost, three times the speed” framing is the kind of round-number CEO-speak that signals direction more than measurement. Both points are directionally credible and echo what’s visible in the data flow of Chinese molecules being licensed to Western pharma; just don’t treat the specific figures as audited.

The self-interest to watch: every problem Bourla names — drug pricing, NIH funding, regulation — resolves into “give pharma more favorable policy and more money.” That’s a real argument, but it’s also exactly the argument his job requires him to make. And the ADC and obesity bets are still unproven; he’s narrating wins before the scoreboard is final.

The mother’s-firing-squad story is moving and clearly load-bearing for who he is. It’s also a well-worn part of his public repertoire. None of that makes it less true; it does make it a practiced story rather than a spontaneous one.

Score 7: substantive, candid, and the China material is worth the time, but it’s a CEO making a CEO’s case, and the headline AI framing is more conventional optimism than insight.

Pfizer CEO: How AI Will Reshape the Future of Medicine | Podcast | In Good Company